The IL-1 family of cytokines and receptors in rheumatic diseases
Crossref DOI link: https://doi.org/10.1038/s41584-019-0277-8
Published Online: 2019-09-12
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dinarello, Charles Anthony
Text and Data Mining valid from 2019-09-12
Version of Record valid from 2019-09-12
Article History
Accepted: 18 July 2019
First Online: 12 September 2019
Competing interests
: C.A.D. serves as chair of the SAB of Olatec Therapeutics, LLC, which develops the NLRP3 inhibitor OLT1177 (Dapansutrile).